Investigation of serum proteome homeostasis during radiation therapy by a quantitative proteomics approach.
Radiotherapy
proteomics
skin lesions
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
31 07 2019
31 07 2019
Historique:
received:
07
12
2018
revised:
11
06
2019
accepted:
08
07
2019
pubmed:
14
7
2019
medline:
19
8
2020
entrez:
14
7
2019
Statut:
epublish
Résumé
The purpose of the present study is to analyze the serum proteome of patients receiving Radiation Therapy (RT) at different stages of their treatment to discovery candidate biomarkers of the radiation-induced skin lesions and the molecular pathways underlying the radiation signatures. Six stages of RT treatment were monitored from patients treated because of brain cancer: before starting the treatment, during the treatment (four time points), and at 4 weeks from the last RT dose. Serum samples were analyzed by a proteomics approach based on the Data Independent Acquisition (DIA) mass spectrometry (MS). RT induced clear changes in the expression levels of 36 serum proteins. Among these, 25 proteins were down- or up-regulated significantly before the emergence of skin lesions. Some of these were still deregulated after the completion of the treatment. Few days before the appearance of the skin lesions, the levels of some proteins involved in the wound healing processes were down-regulated. The pathway analysis indicated that after partial body irradiation, the expression levels of proteins functionally involved in the acute inflammatory and immune response, lipoprotein process and blood coagulation, were deregulated.
Identifiants
pubmed: 31300526
pii: BSR20182319
doi: 10.1042/BSR20182319
pmc: PMC6663990
pii:
doi:
Substances chimiques
Blood Proteins
0
Proteome
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2019 The Author(s).
Références
Eur J Cancer Care (Engl). 2002 Mar;11(1):33-43
pubmed: 11966833
J Immunol Methods. 2002 May 1;263(1-2):43-55
pubmed: 12009203
J Leukoc Biol. 2002 Sep;72(3):462-9
pubmed: 12223513
Histol Histopathol. 2003 Apr;18(2):425-33
pubmed: 12647793
Oncology (Williston Park). 2003 Dec;17(12):1767-79; discussion 1779-82, 1791-2
pubmed: 14723014
Biochem Soc Trans. 2005 Apr;33(Pt 2):401-5
pubmed: 15787615
Proteomics. 2005 Nov;5(16):4254-63
pubmed: 16196097
Br J Haematol. 2005 Nov;131(4):417-30
pubmed: 16281932
Int J Radiat Biol. 2006 Sep;82(9):605-39
pubmed: 17050475
Exp Hematol. 2007 Apr;35(4 Suppl 1):96-104
pubmed: 17379094
Proteomics. 2007 Nov;7(21):3992-4002
pubmed: 17960731
Int J Colorectal Dis. 2008 Oct;23(10):947-55
pubmed: 18633626
Endocr Rev. 2008 Dec;29(7):865-97
pubmed: 18824526
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Int J Radiat Biol. 2009 May;85(5):432-47
pubmed: 19365744
Int J Radiat Biol. 1990 Apr;57(4):751-73
pubmed: 1969905
Proteomics Clin Appl. 2008 Jun 18;2(7-8):1065-1086
pubmed: 19746194
Anal Biochem. 2011 Mar 15;410(2):307-9
pubmed: 21144814
N Engl J Med. 2011 Jun 16;364(24):2334-41
pubmed: 21506737
Proteomics. 2011 Aug;11(16):3299-311
pubmed: 21751382
J Radiat Res. 2011;52(5):575-81
pubmed: 21768750
J Biol Chem. 2012 May 25;287(22):18831-42
pubmed: 22451663
J Innate Immun. 2012;4(4):349-60
pubmed: 22455996
Oncol Lett. 2012 Jan;3(1):75-81
pubmed: 22740859
Adv Exp Med Biol. 2013;990:61-86
pubmed: 23378003
J Cell Biol. 2013 Nov 25;203(4):691-709
pubmed: 24385489
Health Phys. 2014 Dec;107(6):555-63
pubmed: 25353241
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1108-1115
pubmed: 26031365
Radiat Oncol. 2015 Sep 22;10:202
pubmed: 26390925
Mol Cells. 2016 Jan;39(1):60-4
pubmed: 26813661
Cell Mol Life Sci. 2016 Oct;73(20):3861-85
pubmed: 27180275
Proteomes. 2013 Jul 10;1(2):40-69
pubmed: 28250398
J Proteomics. 2018 Mar 1;174:9-16
pubmed: 29278786
J Biol Chem. 1983 Feb 10;258(3):1914-20
pubmed: 6687387
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1171-85
pubmed: 7713781
N Engl J Med. 1999 Feb 11;340(6):448-54
pubmed: 9971870